Analysis updated on Nov. 9, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Bruker Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Bruker Corp is a mid-cap company with a market capitalization of $9.34B. It ranks number 8 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
For BRKR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 42.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BRKR included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
| Metric | BRKR | Rank |
|---|---|---|
| Market Cap | $9.34B | 8/25 |
| P/B Ratio | 4.05x | 8/24 |
| Dividend Yield | 0.33% | – |
| EPS | $-0.55 | – |
| Book Value/Share | $15.14 | – |
| Revenue/Share | $23.06 | – |
| FCF/Share | $1.61 | – |
| Metric | BRKR | Rank |
|---|---|---|
| ROE | -5.3% | 8/19 |
| ROA | -2.1% | 7/18 |
| ROIC | -1.5% | 8/20 |
| Gross Margin | 47.7% | 10/19 |
| Operating Margin | -2.0% | 7/21 |
| Net Margin | -3.5% | 7/17 |
| EBT Margin | -2.0% | 8/22 |
| Tax Rate | -59.7% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
| Metric | BRKR | Rank |
|---|---|---|
| Current Ratio | 1.84x | 22/25 |
| Quick Ratio | 0.90x | 23/24 |
| D/E Ratio | 1.53x | 4/24 |
| Financial Leverage | 2.53x | 4/23 |
| Interest Coverage | -8.2x | 10/21 |
| Working Capital | $985M | 7/25 |
| Metric | BRKR | Rank |
|---|---|---|
| Operating Cash Flow | $342M | 8/24 |
| Free Cash Flow | $245M | 7/20 |
| Capital Spending | -$97M | 15/20 |
| OCF Growth YoY | 262.5% | 1/11 |
| FCF/Sales | 7.0% | 7/19 |
| CapEx/Sales | 2.8% | 9/19 |
| Metric | BRKR | Rank |
|---|---|---|
| Asset Turnover | 0.60x | 7/20 |
| Receivables Turnover | 6.2x | 7/19 |
| Inventory Turnover | 1.7x | 14/19 |
| Fixed Assets Turnover | 5.0x | 11/21 |
| Days Sales Outstanding | 59 days | 13/19 |
| Days Inventory | 219 days | 6/19 |
| Payables Period | 41 days | 11/18 |
| Cash Conversion Cycle | 236 days | 5/17 |
| Metric | BRKR | Rank |
|---|---|---|
| Total Revenue | $3.51B | 6/21 |
| Operating Income | -$70M | 16/21 |
| Net Income | -$123M | 18/19 |
| R&D Expense | $387M | 3/21 |
| SG&A Expense | $955M | 7/20 |
| Cost of Goods Sold | $1.84B | 3/19 |
| Metric | BRKR | Rank |
|---|---|---|
| Dividends Per Share | $0.20 | – |
| Shares Outstanding | 152M | – |
| EPS Growth | -787.5% | 7/7 |
| Total Current Assets | $2.16B | 37.0% of assets |
| Cash & Short-term Investments | $120M | 2.1% of assets |
| Accounts Receivable | $564M | 9.7% of assets |
| Inventory | $1.10B | 18.9% of assets |
| Total Liabilities | $3.52B | 60.4% of assets |
| Short-term Debt | $964M | 16.5% of assets |
Companies classified under the same SEC industry code as Bruker Corp (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BRKR Bruker Corp | $9.34B | |
| A Agilent Technologies, Inc. | $49.27B | |
| WAT Waters Corp /De/ | $44.51B | |
| MTD Mettler Toledo International Inc/ | $34.51B | |
| ILMN Illumina, Inc. | $32.23B | |
| RVTY Revvity, Inc. | $17.31B | |
| AVTR Avantor, Inc. | $10.48B | |
| BIO Bio-Rad Laboratories, Inc. | $10.20B | |
| TXG 10x Genomics, Inc. | $7.72B | |
| ALMR Alamar Biosciences, Inc. | $1.95B | |
| CTKB Cytek Biosciences, Inc. | $758M | |
| PACB Pacific Biosciences Of California, Inc. | $702M | |
| MASS 908 Devices Inc. | $436M | |
| NAUT Nautilus Biotechnology, Inc. | $284M | |
| BFNH Bioforce Nanosciences Holdings, Inc. | $210M | |
| QTRX Quanterix Corp | $131M | |
| SEER Seer, Inc. | $90M | |
| HBIO Harvard Bioscience Inc | $39M | |
| RPID Rapid Micro Biosystems, Inc. | $35M | |
| PRPO Precipio, Inc. | $33M | |
| EYPT Eyepoint, Inc. | $31M | |
| BNGO Bionano Genomics, Inc. | $13M | |
| LCTC Lifeloc Technologies, Inc | $9M | |
| ASTC Astrotech Corp | $8M | |
| SCND Scientific Industries Inc | $7M |
Bruker Corp (BRKR) delivered 400 basis points of operating margin expansion and 24% non-GAAP EPS growth despite flat organic revenue and a $175 million goodwill impairment.
The prospectus contains all relevant information about the new convertible preferred issue. Here, we will highlight only the most important metrics for our analysis. As the security is still trading ...
BILLERICA, Mass. (AP) — BILLERICA, Mass. (AP) — Bruker Corp. (BRKR) on Wednesday reported a loss of $111.8 million in its third quarter. The Billerica, Massachusetts-based company said it had a loss ...
Our AI scores Bruker Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For BRKR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 42.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Bruker Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 9, 2026.
25 issuers in our coverage, BRKR included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Mettler Toledo International Inc/ (MTD), Illumina, Inc. (ILMN), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
